All In Biotech

Drug Trial Radar · NCT07520240

ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain

A Sequential, Single Ascending Dose, Phase 1b, Randomised, Double-Blind, 2-Arm Study to Investigate the Safety and Tolerability of ITX24-01 Compared With Placebo In Adult Male and Female Patients With Select Types of Severe Chronic Neck- And Lower Back Pain

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jan 31, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Interventional AnalgesiX Inc.Industry
Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a single ascending dose (SAD), single-center, randomised, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 in patients with severe chronic zygapophysial joint pain (facet joint pain). The study consists of three dose escalation cohorts and one extension cohort.

Conditions

  • Facet Joint Pain

Interventions

  • ITX24-01Drug

    Fluoroscopy guided local administration by the medial branch block (MBB) route. Dosage form: liquid. Frequency of administration: once (single dose).

  • Normal Saline (0.9% NaCl)Drug

    Placebo (negative control). Dosage form: liquid. Frequency of administration: once (single dose).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of ITX24-01 or placebo delivered locally by the medial branch block (MBB) route in adult participants with severe chronic zygapophysial joint painTime frame: During the screening period, on the day of ITX24-01 administration, and up to 6 weeks of follow-up.
  2. Tolerability of ITX24-01 or placebo delivered locally by the medial branch block (MBB) route in adult participants with severe chronic zygapophysial joint painTime frame: At pre-specified time points up to 6 hours after administration of the investigational medicinal product (IMP).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sydney Pain Management Centre

    Wahroonga, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.